TRIM45 Inhibitors

Chemical inhibitors of TRIM45 operate by targeting the ubiquitin-proteasome pathway, which is crucial for the protein's function in tagging other proteins for degradation. MG-132, Epoxomicin, Lactacystin, Bortezomib, Carfilzomib, Oprozomib, Marizomib, Ixazomib, Delanzomib, Nelfinavir, Withaferin A, and Celastrol are all inhibitors that can interfere with this pathway, thus functionally inhibiting TRIM45. MG-132, for instance, obstructs the ubiquitin-proteasome pathway, potentially preventing TRIM45 from carrying out its role as an E3 ubiquitin ligase. Similarly, Epoxomicin and Lactacystin irreversibly and reversibly inhibit the proteasome, respectively, which can lead to an accumulation of TRIM45 substrates and thus impede its function. Bortezomib and Carfilzomib bind to proteasome subunits, hindering the degradation process TRIM45 is involved in, which can result in the functional inhibition of TRIM45's activity.

Continuing with this theme, Oprozomib targets the proteasome's CT-L activity, which can impede the protein turnover process facilitated by TRIM45. Marizomib binds to the 20S proteasome and can interfere with the protein catabolism that TRIM45 is implicated in. Ixazomib selectively inhibits the 20S proteasome, impacting the protein regulatory functions controlled by TRIM45. Delanzomib inhibits the proteasome's chymotrypsin-like activity, creating a bottleneck in the pathway where TRIM45 operates, thus hindering its function. Nelfinavir, while primarily known as a protease inhibitor, can also disrupt proteasomal degradation pathways crucial for TRIM45's activity. Withaferin A and Celastrol both disrupt proteasomal activity, leading to protein accumulation that TRIM45 would typically ubiquitinate and degrade, which in turn can lead to the functional inhibition of TRIM45. These chemical inhibitors consequently prevent TRIM45 from executing its role in the regulated destruction of intracellular proteins.